Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88175892 |
LAW OFFICE ASSIGNED |
LAW OFFICE 121 |
MARK SECTION |
MARK |
ADAXIQ (see, http://uspto.report/TM/88175892/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
ADAXIQ |
OWNER SECTION (current) |
NAME |
Revance Therapeutics, Inc |
MAILING ADDRESS |
7555 Gateway Boulevard |
CITY |
Newark |
STATE |
California |
ZIP/POSTAL CODE |
94560 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
Revance Therapeutics, Inc. |
MAILING ADDRESS |
7555 Gateway Boulevard |
CITY |
Newark |
STATE |
California |
ZIP/POSTAL CODE |
94560 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Maren C. Perry |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
nytrademarks@kslaw.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
mperry@kslaw.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Maren C. Perry |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
nytrademarks@kslaw.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
mperry@kslaw.com |
DOCKET/REFERENCE NUMBER |
13720.104045 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders,
headaches, wrinkles, hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; pharmaceutical preparations,
namely, peptide substrates for use in the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, sports injuries, namely, injured or
torn skin, muscle, ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; body creams, lotions and gels for medical purposes; eye creams, lotions and gels for medical
purposes |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
3 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
06/04/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/mcp/ |
SIGNATORY'S NAME |
Maren C. Perry |
SIGNATORY'S POSITION |
Attorney of Record, New York Bar member |
DATE SIGNED |
11/09/2020 |
SIGNATORY'S PHONE NUMBER |
(212) 556-2128 |
FILING INFORMATION |
SUBMIT DATE |
Mon Nov 09 13:14:21 ET 2020 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XXX.XXX-
20201109131421684282-8817
5892-75074c1e52e1cd86de64
66aac5e01aea9546ac35d258f
944ef8a0658f27b426-DA-142
18053-2020110913125357525
0 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: ADAXIQ (see, http://uspto.report/TM/88175892/mark.png)
SERIAL NUMBER: 88175892
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Revance Therapeutics, Inc, having an address of
7555 Gateway Boulevard
Newark, California 94560
United States
Email: XXXX
Proposed: Revance Therapeutics, Inc., having an address of
7555 Gateway Boulevard
Newark, California 94560
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 06/04/2019.
For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles,
hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; pharmaceutical preparations, namely, peptide
substrates for use in the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, sports injuries, namely, injured or torn skin, muscle,
ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; body creams, lotions and gels for medical purposes; eye creams, lotions and gels for medical purposes
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the third extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
Maren C. Perry
PRIMARY EMAIL FOR CORRESPONDENCE: nytrademarks@kslaw.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): mperry@kslaw.com
Correspondence Information (proposed):
Maren C. Perry
PRIMARY EMAIL FOR CORRESPONDENCE: nytrademarks@kslaw.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): mperry@kslaw.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /mcp/ Date Signed: 11/09/2020
Signatory's Name: Maren C. Perry
Signatory's Position: Attorney of Record, New York Bar member
Signatory's Phone: (212) 556-2128
RAM Sale Number: 88175892
RAM Accounting Date: 11/09/2020
Serial Number: 88175892
Internet Transmission Date: Mon Nov 09 13:14:21 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-202011091314216
84282-88175892-75074c1e52e1cd86de6466aac
5e01aea9546ac35d258f944ef8a0658f27b426-D
A-14218053-20201109131253575250